期刊
CANCER LETTERS
卷 326, 期 2, 页码 135-142出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.07.030
关键词
Panobinostat; Bortezomib; Leukemia; AKT; NF-kappa B
类别
In this study, we investigated the synergistic effects of panobinostat and bortezomib on adriamycin-resistant HL60/ADR cells and refractory acute myelogenous leukemia (AML) primary cells. Combination of both agents had synergistic cytotoxicity on these cells, and increased the sensitivity of HL60/ADR cells to adriamycin. Panobinostat plus bortezomib was shown to modulate multiple apoptotic and drug metabolic related molecules, including activation of caspases, down-regulation of XIAP. Bcl-2 and MRP1. These effects were likely to be mediated via inhibition of AKT and NF-kappa B pathways. These findings provide evidence for clinic protocols using panobinostat and borezomib to overcome drug resistance in refractory AML patients. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据